School of Medicine

Wayne State University School of Medicine

Faculty Profile

Alexandros C. C. Tselis, M.D., Ph.D.
Professor of Neurology, Director of Neuroinfectious Disease Program
313-745-4275; 313 577-1243

Dr. Tselis, MD, PhD. is currently Professor of Neurology at Wayne State University. His interests include infectious and inflammatory diseases of the nervous system, including the neurological complications of HIV disease, as well as viral encephalitis and multiple sclerosis. He has been listed in Best Doctors in America, and is Vice Chief of Neurology at Detroit Receiving Hospital. He is on the editorial board of the Journal of the Neurological Sciences. In 2009 he was appointed Fellow of the American Academy of Neurology. His research has been funded by the AIDS consortium.

McGill University, BSc, 1978
Brown University, PhD (Physics), 1983
University of Miami, MD, 1987
Northwestern University, 1988-1989, Duke University, 1989-1991
Purdue University, 1983-1985, University of Pennsylvania, 1991-1994

Multiple sclerosis and related diseases, viral encephalitis, Infectious diseases of the nervous system, HIV and its neurological complications.


Tselis A and Lisak RP. Recent developments in acute disseminated encephalomyelitis and isolated central nervous system demyelinative syndromes. Curr. Opinion in Neurol. 1995; 8:227 � 229

Arribas J, Clifford DB, Storch GA and Tselis A. Cytomegalovirus encephalitis. Ann Intern Med. 1996; 125: 577 - 587.

Tselis A, Duman R, Storch GA, Lisak RP. Epstein-Barr virus encephalomyelitis diagnosed by polymerase chain reaction: detection of the genome in the CSF. Neurology, 1997;48: 1351 - 1355.

Price RW, Yiannoutsos C, Clifford DB, Zaborski L, Tselis AC, Sidtis JJ, Cohen B, Hall C, Erice A, Henry K for the ACTG and NeuroAIDS Research Consortium 811 and 810 Study Team. Neurologic outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS 1999; 13: 1677 - 1685.

Nikhar N, Shah J, Tselis A, Lewis RA. Primary neurosarcoidosis: diagnostic and therapeutic issues. The Neurologist 2000;6: 126 - 133. Tselis A and Booss J. Prognosis of Viral Encephalitis. Chapter in Prognosis of Neurological Disease. Evans RW, Baskin DS and Yatsu F, editors. New York, Oxford University Press, 2000.

Tselis A and Lavi E. Cytomegalovirus infection of the adult nervous system. Chapter 4 in Infections of the Nervous System. Kennedy PGE and Davis L, editors. London, Butterworth-Heinemann, 2000.

Tselis A. Cytomegalovirus encephalitis. Curr Treat Op Infect Dis 2001; 3:493-496.

Tselis A. Acute disseminated encephalomyelitis. Curr Treat Op Neurology 2001; 3: 537-542.

Tselis A. Viral meningitis and encephalitis. Conn�s Current Therapy, 54th Edition. Rakel RE and Bope ET, editors. Philadelphia, WB Saunders. 2002.

Tselis A. Epstein-Barr virus and the nervous system. Chapter in Clinical Neurovirology. Berger JR and Nath A, editors. Marcel Dekker, New York. 2003.

Li J, Loeb JA, Shy ME, Shah AK, Tselis AC, Kupsky WJ, Lewis RA. Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol 2003; 53:703-710

Liu J, Brown P, Tselis AC. Unilateral Retrobulbar Optic Neuritis due to varicella-zoster virus in a patient with AIDS. A case report and a review of the literature. J Neurol Sci 2005; 237: 97-101.

Tselis AC and Jenson HB, Editors. Epstein-Barr Virus. Taylor and Francis, New York, New York, March 2006.

Boster A, Hreha S, Bao F, Penmesta A, Tselis A, Endress C, Zak I, Perumal J, Caon C, Vazquez J, Tyler K, Racke M, Khan O. Progressive multifocal leukoencephalopathy: and relapsing-remitting MS. Arch Neurol 2009; 66: 593-599

Tselis A. Human immunodeficiency virus: biology and general overview of seroconversion and early infection. Chapter 93 in R Lisak, D Truong, WM Carrol, R Bhidayasiri, eds. International Neurology.

Khan OA, Tselis A, Boster A. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.Neurology. 2009 Jun 16;72(24):2134; author reply 2134-5. .

Boster A, Hreha S, Berger JR, Bao F, Penmesta R, Tselis A, Endress C, Zak I, Perumal J, Caon C, Vazquez J, Tyler KL, Racke MK, Millis S, Khan O. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study. Arch Neurol. 2009 May;66(5):593-9.

Tselis A, Perumal J, Caon C, Hreha S, Ching W, Din M, Van Stavern G, Khan O.Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol. 2008 Nov;15(11):1163-7. Epub 2008 Aug 21.

 Boster A, Caon C, Perumal J, Hreha S, Zabad R, Zak I, Tselis A, Lisak R, Khan O. Failure to develop multiple sclerosis in patients with neurologic symptoms without objective evidence. Mult Scler. 2008 Jul;14(6):804-8. Epub 2008 Jun 23.
Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, Lisak R, Khan O. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol. 2008 Jul;15(7):677-80. Epub 2008.

Boster A, Edan G, Frohman E, Javed A, Stuve O, Tselis A, Weiner H, Weinstock-Guttman B, Khan O; Multiple Sclerosis Clinical Research Center, Department of Neurology, Wayne State University School of Medicine. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician.Lancet Neurol. 2008 Feb;7(2):173-83. Review.

Perumal J, Zabad R, Caon C, MacKenzie M, Tselis A, Bao F, Latif Z, Zak I, Lisak R, Khan O. Acute transverse myelitis with normal brain MRI : long-term risk of MS. J Neurol. 2008 Jan;255(1):89-93. Epub 2007 Dec 20.

Sheth SG, Rao CV, Tselis A, Lewis RA. HIV-related peripheral neuropathy and glucose dysmetabolism: study of a public dataset. Neuroepidemiology. 2007;29(1-2):121-4. Epub 2007 Oct 16.
Awards & Honors
  • Director of Continuing Medical Education, Neurology


  • Elected a  Fellow of the American Academy of Neurology (AAN) 2009
  • Associate Editor and Book Review Editor, the Journal of the Neurological Sciences
  • Contributing Editor for the Bulletin of the World Federation of Neurology (WFN)
  • Listed in Best Doctors in America and Best Doctors in Michigan
Other Information

New research funding awarded in 2011

�An Exploratory, Non-Conventional, Advanced MRI Study to Examine the Neuroprotective Effect of Azilect Added to Copaxone in Patients with RRMS.� Sponsor: Teva Pharmaceuticals, Ltd. Omar Khan, PI, Alexandros Tselis, co-PI.

�JCV Antibody Program in Patients with Relapsing Multiple Sclerosis STRATIFY 2.� Sponsor: Biogen, Inc. Omar Khan, PI, Alexandros Tselis, co-PI.

New research funding awarded in 2010

�A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active-Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β-1a) to Natalizumab in Subjects with Relapsing‑Remitting Multiple Sclerosis (Surpass Study).� Sponsor: Biogen Idec. Omar Khan, PI, Robert Lisak and Alexandros Tselis, co-PIs.

�Glatiramer Acetate Low-Frequency Adminitrsation (GALA) study. A phase III randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of glatiramer acetate 40 mg subcutaneously three times a week compared to placebo in relapsing-remitting multiple sclerosis.� Sponsor: Teva Pharmaceuticals. Omar Khan, PI, Robert Lisak, Alexandros Tselis co-PIs.
�A Phase 3 Extension Study of Intravenous Low- and High-Dose Alemtuzumab to Three Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Patients with Relapsing-Remitting Multiple Sclerosis Who Have Completed Core Phase III (MS CARE I and II) and CAMMS 223 studies.� Sponsor: Genzyme. Omar Khan, PI, Robert Lisak and Alexandros Tselis co-PIs.
�Extension study to evaluate the efficacy and safety of teriflunomide (HMR1726D) in reducing the frequency of relapses and delaying the accumulation of physical disability in subjects with multiple sclerosis with relapses.� Sponsor: Sanofi-Aventis. Omar Khan, PI, Robert Lisak and Alexandros Tselis, co-PIs.
�An Exploratory, Non-Conventional, Advanced MRI Study to Examine the Neuroprotective Effect of Azilect Added to Copaxone in patients with RRMS. Sponsor: Teva Pharmaceuticals, Ltd. Alexandros Tselis, PI, Omar Khan, co-PI.
�A 6-month, Randomized, Active Comparator, Open-label, Multi- Center Study to Evaluate Patient Out Comes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC).� Sponsor: Novartis Pharmaceuticals. Omar Khan, PI and Alexandros Tselis, co PI.